Adalimumab ‘safe and effective’ in paediatric ulcerative colitis
The findings come from the largest trial yet evaluating a biologic therapy in children with the disease, researchers say
Adalimumab provides clinically meaningful rates of remission and response in children with moderate-to-severe ulcerative colitis, clinical trial results show.
Overall, 37% of children on the medication had a positive response.
